Verve Therapeutics (NASDAQ:VERV) Given Market Perform Rating at Lifesci Capital
Lifesci Capital restated their market perform rating on shares of Verve Therapeutics (NASDAQ:VERV – Free Report) in a report published on Wednesday,Benzinga reports. They currently have a $12.00 target price on the stock. A number of other equities analysts have also recently commented on VERV. Canaccord Genuity Group cut shares of Verve Therapeutics from a […]
Lifesci Capital restated their market perform rating on shares of Verve Therapeutics (NASDAQ:VERV – Free Report) in a report published on Wednesday,Benzinga reports. They currently have a $12.00 target price on the stock. A number of other equities analysts have also recently commented on VERV. Canaccord Genuity Group cut shares of Verve Therapeutics from a […]
